Drug intelligence / Profile preview

ONC007

Development stage: Preclinical
Lead developer: OncoPrecision
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics

Overview

ONC007 is an early-stage oncology research program being developed by OncoPrecision for the treatment of multiple myeloma. The program is currently in the target identification (Target ID) stage, leveraging OncoPrecision's platform which combines patient-derived high-throughput biology with artificial intelligence and machine learning to identify novel therapeutic targets. The program is exploring both antibody-drug conjugate (ADC) and bispecific antibody (BsAb) modalities. Due to its early stage of development, the specific molecular target, payload, and detailed mechanism of action have not yet been publicly disclosed.

Beyond the preview

Go deeper on ONC007.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ONC007.

Explore the full profile